#AUA14 - High incidence of predominant Gleason pattern 4 is associated with low testosterone serum level in localized prostate cancer: An update with 937 patients - Session Highlights

ORLANDO, FL USA (UroToday.com) - Prostate specific antigen (PSA) lacks many qualities of an ideal testing marker. That said, it can be difficult to escape its application when evaluating males for prostate cancer, and it has some proven utility in treatment decisions. Work in recent years has focused on bolstering the utility of PSA through the use of additional measures, or adjusting its use and how it's reported. In this study, Neuzillet and colleagues report on a prospective study evaluating the association of total testosterone with prostate cancer aggressiveness. The aggressiveness of the cancer was measured using predominant Gleason pattern.

auaIt was performed over approximately 2.5 years for patients referred for radical prostatectomy. The biopsy and tissue specimens were analyzed by two uropathologists. A total of 937 patients were enrolled. Of these, 139 with total testosterone (TT) < 3.0 ng/mL had a higher mean weight and BMI than the rest of the cohort (p < 0.001 for both). They observed a predominant Gleason pattern of 4 (prdGP4) in 169 (18%) of patient biopsies and 290 (31%) of prostate specimens after prostatectomy. They found that patients with prdGP4 had a lower TT when compared to patients with prdGP3 (4.4 vs 4.7 ng/mL, p=0.017) and had a higher PSA (10.2 vs 7.7 ng/mL, p < 0.001). Additionally, they observed extraprostatic extension and positive margins more often in the cohort of patients with prdGP4 (55% versus 23%, p < 0.0001).

These results implicate that the TT has a strong association with prdGP4, which cannot be accurately measured using prostate biopsy. Thus, TT may be useful in adjusting PSA and biopsy results to inform a more detailed and specific decision algorithm. Development and validation of such a decision instrument is an interesting hopeful future for this work. However, additional studies regarding the predictive validity of TT and further studies on the measure would be necessary before such an instrument could be implemented and evaluated.

Presented by Yann Neuzillet at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Paris, France

Written by Martin Hofmann, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland